Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C12H10O4 |
| Molecular Weight | 218.2054 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(OC(=CC1=O)C(O)=O)C2=CC=CC=C2
InChI
InChIKey=DFDGRKNOFOJBAJ-UHFFFAOYSA-N
InChI=1S/C12H10O4/c1-12(8-5-3-2-4-6-8)10(13)7-9(16-12)11(14)15/h2-7H,1H3,(H,14,15)
| Molecular Formula | C12H10O4 |
| Molecular Weight | 218.2054 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16389067 | https://www.ncbi.nlm.nih.gov/pubmed/21454438 | https://www.ncbi.nlm.nih.gov/pubmed/17358052 | http://adis.springer.com/drugs/800000311https://www.ncbi.nlm.nih.gov/pubmed/12522134Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16389067 | http://adisinsight.springer.com/drugs/800000311 | https://www.ncbi.nlm.nih.gov/pubmed/6818976 | https://www.ncbi.nlm.nih.gov/pubmed/3314798
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16389067 | https://www.ncbi.nlm.nih.gov/pubmed/21454438 | https://www.ncbi.nlm.nih.gov/pubmed/17358052 | http://adis.springer.com/drugs/800000311https://www.ncbi.nlm.nih.gov/pubmed/12522134
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16389067 | http://adisinsight.springer.com/drugs/800000311 | https://www.ncbi.nlm.nih.gov/pubmed/6818976 | https://www.ncbi.nlm.nih.gov/pubmed/3314798
Acifran (AY-25,712), an uncommercialized Ayerst compound exerting lipid-lowering activity in vivo, has been shown to also elicit similar effects as niacin in preliminary clinical testing and has been shown to bind to both high affinity (HM74A; GPR109A) and low affinity (HM74; GPR109B) niacin receptors. The EC50 values of the separated acifran enantiomers for the GPR109a and 109b receptors showed that, as with acifran itself, the (+)-enantiomers were essentially twice as active as the racemic mixtures, whereas the activity of the (-)-enantiomers was more variable and highly dependent on purity. S-enantiomer of acifran is the active principle. All of the activity of racemic acifran could be attributed to the (S)-enantiomer, and hence, from this precedent, (+)-enantiomers would be assigned to the S-configuration. However, the absolute configuration was not confirmed experimentally.
Originator
Sources: http://adis.springer.com/drugs/800000311 | https://www.ncbi.nlm.nih.gov/pubmed/17358052http://adisinsight.springer.com/drugs/800000311
Curator's Comment: # Ayerst (now Wyeth)
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 2.1 µM [EC50] | |||
Target ID: CHEMBL4421 |
20.0 µM [EC50] | ||
Target ID: CHEMBL3785 |
0.52 µM [EC50] | ||
Target ID: CHEMBL4421 |
3.0 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.22 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2295219 |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACIFRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4.26 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2295219 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACIFRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
16.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2295219 |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACIFRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
15.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2295219 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACIFRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2295219 |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACIFRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2295219 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACIFRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12.2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2295219 |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACIFRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
300 mg 3 times / day multiple, oral Highest studied dose Dose: 300 mg, 3 times / day Route: oral Route: multiple Dose: 300 mg, 3 times / day Sources: Page: p.315 |
unhealthy, ADULT n = 13 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 13 Sources: Page: p.315 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecular identification of high and low affinity receptors for nicotinic acid. | 2003 Mar 14 |
|
| Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug? | 2004 Mar |
|
| (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. | 2005 Jul 22 |
|
| Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. | 2006 Feb 28 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:24:08 GMT 2023
by
admin
on
Sat Dec 16 09:24:08 GMT 2023
|
| Record UNII |
61IZ92GN57
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m999
Created by
admin on Sat Dec 16 09:24:08 GMT 2023 , Edited by admin on Sat Dec 16 09:24:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
77103-92-5
Created by
admin on Sat Dec 16 09:24:08 GMT 2023 , Edited by admin on Sat Dec 16 09:24:08 GMT 2023
|
PRIMARY | |||
|
61IZ92GN57
Created by
admin on Sat Dec 16 09:24:08 GMT 2023 , Edited by admin on Sat Dec 16 09:24:08 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
|
RACEMATE -> ENANTIOMER |
